What You Should Know:
– Amgen, a global leader in biotechnology, is embarking on a groundbreaking venture: Project Freyja.
– The new initiative will harness the power of an NVIDIA DGX SuperPOD, christened after the Norse goddess of prediction, to accelerate drug discovery and development through AI-powered insights from one of the world’s largest human datasets.
Advance Drug Discovery Using NVIDIA DGX SuperPOD-Powered Insight
- Human Diversity Atlas: Freyja will map the landscape of human genetic variation, creating an invaluable atlas for identifying drug targets and disease-specific biomarkers. This will pave the way for personalized medicine, tailoring treatments to individual patients based on their unique genetic makeup.
- Precision Medicine Revolution: Equipped with Freyja’s AI capabilities, Amgen researchers will develop cutting-edge precision medicine models, potentially enabling the creation of individualized therapies for a multitude of serious diseases.
- Diagnostics Made Easy: By identifying novel biomarkers, Freyja will empower the development of accurate and efficient diagnostics for monitoring disease progression and response to treatment.
Unleashing the Power of Data
- DGX SuperPOD: A powerhouse of computing, the SuperPOD boasts 248 NVIDIA H100 Tensor Core GPUs, allowing Amgen to train state-of-the-art AI models in days, not months. This dramatically accelerates the pace of data analysis and discovery.
- 200 Petabytes of Insights: Freyja will draw upon deCODE genetics’ vast library of deidentified human data, exceeding 200 petabytes, encompassing nearly 3 million individuals. This unparalleled resource provides a unique window into human diversity and its role in health and disease.
“Freyja embodies our commitment to leveraging the convergence of technology and biotechnology. By combining our world-class human data with NVIDIA’s cutting-edge AI technology, we are poised to unlock a new era of drug discovery,” said David M. Reese, Amgen’s Chief Technology Officer.